ReviewBiology2026
Extracellular Matrix Remodeling as a Mechanobiological Driver of Breast Cancer Aggressiveness: Comparative Oncology, Multi-Omics, and Artificial Intelligence Perspectives.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The extracellular matrix (ECM) is increasingly recognized as an active regulator of breast cancer progression rather than a passive structural scaffold. This narrative review examines how ECM remodeling contributes to tumor aggressiveness through changes in matrix composition, collagen architecture, tissue stiffness, mechanotransduction, stromal permissiveness, immune and metabolic programs, invasion, metastasis and therapeutic response. A structured narrative search of literature published from 1981 to June 2026 was used to support this synthesis. Evidence from breast cancer studies indicates that collagens, fibronectin, laminins, proteoglycans, matricellular proteins, ECM-remodeling enzymes, and matrix-crosslinking pathways regulate integrin-FAK/Src, RhoA-ROCK, PI3K-AKT, MAPK, TGF-β/SMAD, Wnt/β-catenin, and YAP/TAZ signaling. Spontaneous canine mammary tumors are discussed as complementary comparative models that may preserve selected tumor-stroma-ECM interactions under naturally occurring disease conditions while requiring cautious interpretation due to species-specific biological and clinical differences. Proteomics, lipidomics, metabolomics, spatial omics, digital pathology, and artificial intelligence may support ECM-informed biomarker discovery and response prediction. However, translational application requires standardized pathology, reproducible assays, harmonized metadata, external validation, model interpretability, and clinically meaningful endpoints. Overall, ECM-informed comparative oncology is best viewed as a framework grounded in rigorous validation for identifying matrix-defined tumor phenotypes and prioritizing future biomarker and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.